Lab
Sea Level Labs LLC
Sea Level Labs LLC was paid $145K by Medicaid between Apr 2018 and Oct 2024, across 61 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 23% of everything it billed.
33Billing provider infoSEA LEVEL LABS LLC
GULF BREEZE, FL 32563
GULF BREEZE, FL 32563
33aNPI1164962122assigned 02/24/2017
33bProvider typeClinical Medical Laboratory
28Total paid$145K
24GClaims71,432
24DCodes billed61
24AFirst – last monthApr 2018 – Oct 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#92 of 225
Median peer was paid$74K
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 603 | $15K | |
| 2019 | 4,127 | $50K | |
| 2020 | 11,811 | $5K | |
| 2021 | 13,184 | $22K | |
| 2022 | 15,701 | $21K | |
| 2023 | 19,358 | $29K | |
| 2024incomplete | 6,648 | $5K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 23% | 1,669 | 1,375 | $34K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 23% | 8,731 | 2,086 | $33K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 16% | 1,126 | 945 | $23K |
| 81003 | 7.5% | 2,359 | 1,624 | $11K | |
| 80346 | 3.8% | 170 | 156 | $6K | |
| 83992 | 3.1% | 186 | 164 | $5K | |
| 80361 | 3.0% | 164 | 151 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.4% | 17,060 | 2,108 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.2% | 544 | 401 | $3K |
| 87481 | 1.2% | 5,851 | 2,079 | $2K | |
| 80053 | Comprehensive metabolic panel | 1.2% | 1,250 | 908 | $2K |
| 80348 | 1.1% | 170 | 156 | $2K |
49 more codes
| 81007 | 1.1% | 879 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,758 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,757 | $1K |
| 80324 | <1% | 184 | $1K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,500 | $1K |
| 87640 | <1% | 3,029 | $1K | |
| 83880 | <1% | 232 | $940.90 | |
| 87641 | <1% | 3,110 | $868.66 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,129 | $850.40 |
| 80364 | <1% | 167 | $842.13 | |
| 87653 | <1% | 3,032 | $827.45 | |
| 80355 | <1% | 178 | $763.20 | |
| 80359 | <1% | 179 | $758.95 | |
| 87500 | <1% | 2,793 | $686.68 | |
| 80368 | <1% | 180 | $654.00 | |
| 81002 | <1% | 276 | $612.32 | |
| 80061 | Lipid panel | <1% | 655 | $473.78 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 617 | $456.86 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 660 | $267.92 |
| 82607 | <1% | 306 | $243.34 | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 91 | $217.83 |
| 80323 | <1% | 20 | $207.00 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 33 | $140.92 |
| 80336 | <1% | 180 | $129.42 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 120 | $120.25 |
| 80356 | <1% | 171 | $115.74 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 1,249 | $105.77 |
| 80349 | <1% | 168 | $105.45 | |
| 80353 | <1% | 172 | $90.70 | |
| 87631 | <1% | 43 | $76.31 | |
| 80360 | <1% | 178 | $75.75 | |
| 80369 | <1% | 167 | $75.75 | |
| 80332 | <1% | 181 | $75.75 | |
| 80371 | <1% | 171 | $75.75 | |
| 83735 | <1% | 321 | $70.16 | |
| 80366 | <1% | 180 | $65.35 | |
| 80342 | <1% | 15 | $37.80 | |
| 82728 | <1% | 37 | $28.27 | |
| 84439 | <1% | 113 | $26.04 | |
| 82570 | <1% | 68 | $24.55 | |
| 87581 | <1% | 43 | $20.86 | |
| 87541 | <1% | 43 | $20.86 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,414 | $20.32 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 69 | $17.50 |
| 82043 | <1% | 42 | $17.11 | |
| 87540 | <1% | 43 | $11.92 | |
| 82746 | <1% | 76 | $8.88 | |
| 83540 | <1% | 52 | $7.39 | |
| 83721 | 0% | 71 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROWN, WILLIAM (VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Warehouse Primary Care & Specialty Clinic INC. | Cullman, AL | $48K |
| Breeze Counseling Services | Earleville, MD | $48K |
| W. Bruce Brown MD, PA. | Russellville, AR | $26K |
| William P. Brown, D.C., INC. | Perrysburg, OH | $21K |
| Kentucky Foot & Ankle Solutions PLLC | Louisville, KY | $10K |
| WRB Enterprises INC. | Mayfield, KY | $3K |
| Brownpharmacy LLC | Wilmington, NC | $1K |
| Triad Neurosurgical Associates, P.A. | Winston Salem, NC | $869.52 |
| The Urology Clinic of Greenwich PC | Old Greenwich, CT | $281.63 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.